| Issue Date | Title | Author(s) |
| 2-Nov-2023 | Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up | Song, Yuqin; Zhou, Keshu; Li, Dengju; Hu, Jianda; Zou, Dehui; Gao, Sujun; Yang, Haiyan; Zhang, Huilai; Ji, Jie; Xu, Wei; Feng, Ru; Jin, Jie; Lyu, Fangfang; Fang, Cheng; Xu, Sheng; Zhu, Jun |
| 2023 | Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis | Song, Yuqin; Zhou, Keshu; Zou, Dehui; Li, Dengju; Hu, Jianda; Yang, Haiyan; Zhang, Huilai; Ji, Jie; Xu, Wei; Jin, Jie; Lv, Fangfang; Feng, Ru; Gao, Sujun; Zhou, Daobin; Tam, Constantine S.; Simpson, David; Wang, Michael; Phillips, Tycel J.; Opat, Stephen; Fang, Cheng; Sun, Shaohui; Zhu, Jun |
| 15-Nov-2022 | Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis | Song, Yuqin; Zhou, Keshu; Zou, Dehui; Li, Dengju; Hu, Jianda; Yang, Haiyan; Zhang, Huilai; Ji, Jie; Xu, Wei; Jin, Jie; Lv, Fangfang; Feng, Ru; Gao, Sujun; Zhou, Daobin; Tam, Constantine S.; Simpson, David; Wang, Michael L.; Phillips, Tycel J.; Opat, Stephen; Fang, Cheng; Sun, Shaohui; Zhu, Jun |
| 15-Apr-2023 | The Oral PI3Kd Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial | Wang, Tingyu; Sun, Xiuhua; Qiu, Lihua; Su, Hang; Cao, Junning; Li, Zhiming; Song, Yuqin; Zhang, Li; Li, Dengju; Wu, Huijing; Zhang, Wei; Li, Junmin; Zhou, Keshu; Zhou, Hui; Yang, Yu; Li, Zhifeng; Cen, Hong; Cai, Zhen; Zhang, Zhihui; Fu, Weijun; Jin, Jie; Li, Fei; Wu, Weixin; Gu, Xuekui; Zhu, Weiliang; Liu, Lihong; Li, Zengjun; Yi, Shuhua; Bao, Hanying; Xu, Zusheng; Qiu, Lugui |
| 2023 | Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study | Deng, Lijuan; Li, Zhiming; Zhang, Huilai; Huang, Haiwen; Hu, Jianda; Liu, Lihong; Liu, Ting; Jin, Jie; Zhu, Zunmin; Li, Wenyu; Huang, Zhenqian; Huang, Wenrong; Zhou, Keshu; Yang, Haiyan; Zhang, Mingzhi; Ding, Kaiyang; Zhou, Hui; Hu, Yu; Shuang, Yuerong; Cao, Junning; Gao, Sujun; Li, Dengju; Sun, Zimin; Zhang, Qingyuan; Yi, Shuhua; Ji, Chunyan; Zhang, Liansheng; Hou, Cheng; Du, Yue; Wang, Weige; Zhao, Renbin; Song, Yuqin; Zhu, Jun |
| Apr-2022 | A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies | Song, Yuqin; Sun, Mingyuan; Qi, Junyuan; Xu, Wei; Zhou, Jianfeng; Li, Dengju; Li, Jianyong; Qiu, Lugui; Du, Chenmu; Guo, Haiyi; Huang, Jane; Tang, Zhiyu; Ou, Ying; Wu, Binghao; Yu, Yiling; Zhu, Jun |
| Feb-2023 | Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis | Xu, Wei; Yang, Shenmiao; Zhou, Keshu; Pan, Ling; Li, Zengjun; Gao, Sujun; Zhou, Daobin; Hu, Jianda; Feng, Ru; Huang, Haiwen; Wang, Tingyu; Li, Dengju; Ji, Meng; Guo, Haiyi; Zhao, Xia; Wu, Binghao; Yu, Yiling; Wang, Yu; Huang, Jane; Novotny, William; Li, Jianyong |
